Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis.
Leukocytapheresis (LCAP) with a leukocyte removal filter column was administered for 45 patients with ulcerative colitis (UC). We evaluated changes in the leukocyte count and the differential percentages during LCAP. Cytokine production was assessed from each patient's peripheral mononuclear cells or monocytes. Flow cytometry was performed to assess the removal rates of activated cells and adhesion molecule positive cells by LCAP. Clinical improvement was recognized in 35 of 45 patients during intensive LCAP therapy, and it continued throughout maintenance therapy in 32 patients (71.1%). The leukocyte count was decreased to about 40% during the first 30 min, but it increased to approximately 170% at 20 min after the completion of LCAP. The concentration of tumor necrosis factor (TNF)alpha before LCAP in the effective group was higher than it was in either the ineffective group or the control group. Its level decreased to near normal range after LCAP. In the effective group, the concentrations of interleukin (IL)-1beta, IL-2, interferon (IFN)gamma, and IL-8 were near the normal upper limits before LCAP; however, they had decreased after LCAP. The concentration of IL-4 increased after LCAP. In the ineffective group, in contrast, the concentrations had been at or near normal before the initial LCAP treatment. Flow cytometry study revealed that LCAP could remove the activated cells and adhesion molecule positive cells more effectively. The clinical improvement and the changes observed before and after LCAP therapy suggest that LCAP is able to intervene in the causal mechanism(s) of UC.
Sawada
K
K
Department of Internal Medicine IV, Hyogo College of Medicine, Nishinomiya, Japan.
Ohnishi
K
K
Kosaka
T
T
Chikano
S
S
Yokota
Y
Y
Egashira
A
A
Izawa
H
H
Yamamura
M
M
Amano
K
K
Satomi
M
M
Shimoyama
T
T
D001772:Blood Cell Count; D015815:Cell Adhesion Molecules / Q000097:blood; D003093:Colitis, Ulcerative / Q000097:blood / Q000276:immunology / Q000628:therapy*; D005374:Filtration / Q000295:instrumentation; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007378:Interleukins / Q000096:biosynthesis; D007937:Leukapheresis / Q000295:instrumentation / Q000379:methods*; D007962:Leukocytes / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D015815:Cell Adhesion Molecules; D006684:HLA-DR Antigens; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma